La Jolla, CA, United States of America

Richard A Lerner

USPTO Granted Patents = 87 

 

 

Average Co-Inventor Count = 3.1

ph-index = 26

Forward Citations = 3,070(Granted Patents)


Inventors with similar research interests:


Location History:

  • San Diego, CA (US) (1988)
  • La Jolla, CA (US) (1985 - 2022)

Company Filing History:


Years Active: 1985-2024

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Personalized Cancer Therapy
TrkB Agonist Antibodies
Functional Polypeptides
GPCR Agonist Polypeptides
Immunological Tolerance
Heterodimeric Receptor Libraries
Catalytic Antibodies
Monoclonal Antibodies
Encoded Combinatorial Libraries
Polypeptide Binding Sites
Prodrug Activation
Fatty-Acid Amide Hydrolase
87 patents (USPTO):Explore Patents

Title: Richard A Lerner: Pioneering Personalized Therapies and Ocular Degenerative Disorder Treatments

Introduction:

Richard A Lerner, a distinguished inventor and researcher, is based in La Jolla, California. Known for his groundbreaking work in personalized therapy for cancer and treatments for ocular degenerative disorders, Lerner has made significant contributions to the field of medicine. With 86 patents to his name, his innovations have shaped the landscape of modern healthcare.

Latest Patents:

Lerner's latest patents encompass two areas of medical research. The first involves articles and methods focused on personalized therapy for B cell malignancies, including lymphoma. By utilizing Chimeric Antigen Receptor (CAR) technology, Lerner is paving the way for more effective and individualized cancer treatments.

The second patent revolves around the development of TrkB agonist antibodies for treating ocular degenerative disorders, such as glaucoma. By enhancing TrkB signaling activities, Lerner's research offers promising therapeutic methods to promote the survival and regeneration of retinal ganglion cells, offering new hope for patients suffering from neurodegenerative conditions.

Career Highlights:

Richard A Lerner has made significant contributions to medical research, primarily during his tenure at renowned institutions such as The Scripps Research Institute and the Scripps Clinic and Research Foundation. Throughout his career, Lerner has explored the frontiers of personalized medicine, gene therapy, and immunotherapy and has been instrumental in translating these discoveries into potential treatments.

Collaborations:

Lerner's remarkable contributions have been reinforced through collaborations with highly esteemed colleagues. Notably, he has collaborated with Carlos F Barbas, III and Kim D Janda, two well-known scientists in their respective fields, fostering an environment of innovation, knowledge sharing, and interdisciplinary research. These collaborations have resulted in significant breakthroughs that continue to shape the future of healthcare.

Conclusion:

Richard A Lerner's significant patent portfolio, cutting-edge research, and collaborative efforts have transformed the landscape of medical science. His work in the realms of personalized cancer therapy and ocular degenerative disorder treatments has the potential to revolutionize patient care, further underscoring his status as a remarkable innovator. As we eagerly anticipate what lies ahead, Lerner's contributions will undoubtedly continue to impact the field of medicine and improve the lives of countless individuals.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…